TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01002196

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stimulus fading procedures
Description: Core elements : 1.Behavior techniques (BT's) are used to gradually master the anxiety (stimulus fading and reward).~2. Children are first met at home where they feel most safe, and the BT's are first conducted at home in cooperation with the parents.~3.The same interventions are then continued in the environment where the problem primarily exist (kindergarten / school) not at the clinic.~4.Defocused communication- and interaction is a general treatment principle (e.g. avoid looking directly at the child, sit beside not opposite to the child, no direct questioning, and communication is based upon a motivating activity, not about the child).~5.Frequent and short interventions. 6.Information to parents and teachers on how to communicate with children with SM

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guidance on defocused communication
Description: Guidance and supervision to teachers working with the children with SM. Frequency: Twice during three months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guidance on defocused communication
Description: Guidance and supervision to teachers working with the children with SM. Frequency: Twice during three months
Study: NCT00967343

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor lymphocyte preparation depleted of host functional alloreactive T-cells
Description: Single intravenous infusion with 2x10E6 T-cells/kg
Study: NCT03977363

Intervention type: DRUG
Intervention: Anticoagulant drugs
Description: Anticoagulant drugs
Study: NCT04019860

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training
Description: Three weekly, supervised exercise sessions with high intensity. Each session will last for 30-45 minutes. Intervention period will be seven weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training
Description: Three weekly, supervised exercise sessions with high intensity. Each session will last for 30-45 minutes. Intervention period will be seven weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-Restricted Eating
Description: Restricted daily window of caloric intake to maximum 10 hours. Intervention period will be seven weeks.
Study: NCT02448368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170, 2.5 mg
Description: Fifteen subjects were randomized to 1 of 3 treatment sequences with single doses occurring on Days 1, 5, and 9.
Study: NCT02009592

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin
Description: Both arms receive Rifaximin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin
Description: Both arms receive Rifaximin
Study: NCT03271047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: binimetinib
Description: Orally, twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: binimetinib
Description: Orally, twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: binimetinib
Description: Orally, twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Intravenously (IV) every 4 weeks (Q4W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Intravenously (IV) every 4 weeks (Q4W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Intravenously (IV) every 4 weeks (Q4W)
Study: NCT02008812

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ad sensor
Description: Ad sensor, which was developed for the rapid and sensitive detection of viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-Adenovirus and its Adenovirus antigen present in patients and normal samples.~The system incorporates the use of chip formats. In antibody probing, antibodies are bound as a suitable probe, which specifically and selectively binds targeted molecules (virus antigen) in the test specimens.
Study: NCT04169152

Intervention type: PROCEDURE
Intervention: Cap-assisted endoscopic sclerotherapy
Description: Cap-assisted endoscopic sclerotherapy (CAES) is an innovation technique for having advantages in accurately controlling the injection angle, direction, depth under direct vision of flexible endoscope.
Study: NCT01917916

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for subcutaneous (s.c.) injection.
Study: NCT03271047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Intravenously (IV) every 4 weeks (Q4W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: intravenously (IV) every 8 weeks (Q8W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: intravenously (IV) every 8 weeks (Q8W)
Study: NCT01100528

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa-2b
Description: Given subcutaneously (SC) 3 times a week for 24 weeks
Study: NCT01917916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655064
Description: Solution for subcutaneous (s.c.) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655064
Description: Solution for subcutaneous (s.c.) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655064
Description: Solution for subcutaneous (s.c.) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655064
Description: Solution for subcutaneous (s.c.) injection.
Study: NCT05232188

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous nephrolithotomy
Description: percutaneous nephrolithotomy surgery, 22F amplatz sheath is used in one group, while 28F amplatz sheath is used in the other group.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous nephrolithotomy
Description: percutaneous nephrolithotomy surgery, 22F amplatz sheath is used in one group, while 28F amplatz sheath is used in the other group.
Study: NCT03097146

Intervention type: OTHER
Group type: OTHER
Intervention: comprehensive multidisciplinary stroke care
Description: Patients will be treated in the pathological domain. Some of this treatment will be applied by the outpatient clinic itself (i.e. changes in medical secondary prevention or additional prescriptions, social work interventions), whereas most of it will be referred to other providers, if possible in vicinity to the patients' home. In order to ease treatment prescriptions and allow to measure treatment uptake, patients will also enrol in the case management system Ambulanzpartner. This allows the outpatient center to streamline prescription processes and measure uptake of therapies.
Study: NCT00638053

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: somatropin
Description: Somatropin will be administered as a daily subcutaneous injection; Fixed doses starting with 0.1 mg/day in patients older than 55 years or patients weighing less than 50 kg; all other patients: 0.1 mg/day or 0.2 mg/day (these doses should all be lower than 0.04 mg/kg/week); all patients starting at 0.1 mg/day will have their dose progressively increased in 0.1 mg/day increments to a maximum clinically- and pharmacologically- tolerated plateau dose; all patients starting at 0.2 mg/day will increase in 0.2 mg/day increments; all incremented dose changes will occur at monthly intervals based on IGF-I levels; treatment will continue for 12 months
Study: NCT01174043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib will be administered orally at 150 mg once a day, continuously. Each cycle will be 28 days and there will be no break between the cycles.
Study: NCT01100528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacarbazine
Description: Given IV on days 1 and 29

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies obtained prior to therapy, every 8 weeks while on therapy, and then every 6 months during follow-up
Study: NCT02750865

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Embodied Conversational Agent (ECA)
Description: The ECA is a computer generated character who will interact with the subject on a daily basis via a touch-screen tablet. The system is designed to provide the following functions: (1) medication counseling; (2) physical activity promotion; (3) symptom management and continual screening for adverse events; and (4) alleviation of stress and anxiety. The investigators will augment the system to include: (5) spiritual needs assessment; and (6) advanced care planning.
Study: NCT04438876

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Power Training
Description: The exercise intervention encompassed high-velocity movement, balance, and mobility exercises with the use of body weight and resistance bands as resistance. Participants were instructed to move rapidly during the concentric phase and slowly during the eccentric phase when performing the dynamic exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants either continued the usual exercise program provided by their respective community senior activity centers or their personal exercise routine.
Study: NCT03597477

Intervention type: DRUG
Intervention: Dexmedetomidine
Description: participants were randomly allocated to receive sedation with oral midazolam(0.3 mg/kg) combined with 4 doses of intranasal dexmedetomidine(1.0, 1.5, 2.0, 2.5)

Intervention type: DRUG
Intervention: Dexmedetomidine
Description: participants were randomly allocated to receive sedation with oral midazolam(0.3 mg/kg) combined with 4 doses of intranasal dexmedetomidine(1.0, 1.5, 2.0, 2.5)
Study: NCT00846989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RKI983A
Description: RKI983 0.05 % twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RKI983A
Description: RKI983 0.1 % twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost
Description: Latanoprost 0.005 % once a day
Study: NCT05004506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adductor Canal Block
Description: The anesthesia provider will identify the adductor canal using ultrasound guidance and inject 15ccs of 0.5% marcaine with epinephrine around the saphenous nerve.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intra-articular Injection
Description: receive 20ccs of 2% lidocaine with epinephrine as an intra-articular injection
Study: NCT00093886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clevidipine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nitroglycerin
Study: NCT03808363

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training
Description: Participants assigned to this group will perform a very mild 5-minute warm-up (0 resistance, and 60 rpm), followed by 5 one-minute bouts of high intensity exercise, with 90 seconds between each bout. These bouts will be followed by a 3-minute cool down (0 resistance, and 60 rpm). The high-intensity exercise will be performed at an intensity of 17 on the Borg rating of perceived exertion (RPE) scale (very hard), and the 90 second active rest intervals will be performed at an intensity of 7-9 (very, very light - very light). The exercise will be performed on the NuStep machine 3 times a week for 6 weeks.
Study: NCT01449773

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: n-3 PUFAs
Description: 5 capsules/day in order to provide 3 g/day of n-3 PUFAs.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 capsules/day containing corn and soybean oil
Study: NCT03281551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PZ01 CAR-T cells
Description: Chimeric antigen receptor (CAR) T cells targeting CD19 will be evaluated for safety and efficacy in patients with relapsed/ refractory B-cell Acute Lymphoblastic Leukemia/B cell Lymphoma. The CAR consists of a CD19 targeting antibody scFv with two intracellular signaling domains derived from CD3 zeta and 4-1BB. Autologous T cells will be gene-engineered with the CAR gene using a lentivirus vector. Prior to T cell infusion, the patients will be subjected to preconditioning treatment. After T cell infusion, the patients will be evaluated for 24 months for adverse reactions, persistence of CAR T cells and efficacy.
Study: NCT03747900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: 200 U Botulinum toxin type A injection in the spastic biceps brachii muscle.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A and dry needling.
Description: Dry needling for 4 times in total in the spastic biceps brachii muscle after the Botulinum toxin type A injection.
Study: NCT04500236

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: Surgery under general anesthesia with the use of propofol

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hypno-analgesia
Description: Surgery under Hypnosis session and analgesics
Study: NCT00933244

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: High Dose Vitamin D3
Description: Yellow gel-cap vitamin D3 at 50,000 International Units daily for 15 days then two times a month for 350 days. Daily white placebo pills.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Low Dose Vitamin D3
Description: White gel-cap vitamin D3 at 800 International Units to take orally, daily for 365 days. Intermittent yellow placebo pills.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Yellow gel-cap placebo pills to take orally, daily for 15 days then two times a month for 350 days. White gel-cap placebo pills once daily for 365 days.
Study: NCT02227836

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Allergy Patch Testing
Study: NCT02182674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Combivent HFA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combivent HFA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combivent (CFC)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Combivent (CFC)
Study: NCT05183269

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oncomfort virtual reality monitor (Oncomfort SA, Wavre, Belgium)
Description: Use of the Oncomfort virtual reality monitor
Study: NCT01831440

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: medicine combined CBT
Description: medicine：Clinical routine antidepressant treatment CBT：During the treatment period，weekly for 8 weeks，and monthly for the maintenance phase.Therapists receive group supervision monthly.

Intervention type: DRUG
Group type: OTHER
Intervention: medicine
Description: Participants receive only clinical routine antidepressant treatment,Which include fluoxetine (Prozac); sertraline (Zoloft); paroxetine (Paxil); citalopram (Celexa) ;escitalopram (Lexapro) and fluvoxamine (Luvox). It will be chosen according to special condition of every patient.
Study: NCT01143896

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Depression collaborative care model
Description: The intervention will include a stepped-care model. The 5 steps include symptom and self-management monitoring by a depression care manager (DCM) and the following: 1) watchful waiting, 2) treatment recommendations (counseling or pharmacotherapy), 3) pharmacotherapy recommended by a Clinical Pharmacist, 4) combination pharmacotherapy and specialty mental health counseling, and 5) referral to mental health. The DCM: provides education about depression and depression treatment options; assesses the patient's treatment preferences and barriers, and the patient's current depression severity and mental health comorbidity; initiates a patient self-management plan, and assess treatment adherence. The DCM uses standard alcohol screening and brief intervention. The DCM also screens for street drug use and recommends referral for to the local substance abuse treatment programs.
Study: NCT04000334

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MAP increased to optimize cerebral blood flow
Description: MAP will be increased to 90-100 mmHg with norepinephrine. If TCD is still abnormal with a MAP of 90-100 mmHg, MAP will be increased to 100-110 mmHg. At each step, all CBF determinants will be recorded as well as cardiac output and Veinous jugular oxygen saturation (SvjO2). When TCD is normalized with no complications, MAP will be maintained at 90-100 or 100-110 mmHg during 24 hours.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MAP between 65 and 85 mmHg
Description: MAP will be maintained between 65-85 mmHg, using a norepinephrine infusion as needed.
Study: NCT02179255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Growth Hormone
Description: 1.9 mg (5.7 units) daily injection of Recombinant Human Growth Hormone (HGH) for at least 6 weeks (42 days) continuing into the approximately 14 days of ovulation induction phase of the trial.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follicle Stimulating Hormone
Description: FSH 450 to 600 units per day administered SQ daily dose adjusted based on the patients response starting on day 2 of the 28 day menstrual cycle and continued until Ovulation trigger

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follicle Stimulating Hormone
Description: FSH 450 to 600 units per day administered SQ daily dose adjusted based on the patients response starting on day 2 of the 28 day menstrual cycle and continued until Ovulation trigger
Study: NCT01318070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin and pioglitazone
Description: Alogliptin 12.5mg, tablets, orally, once daily and Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin and pioglitazone
Description: Alogliptin 25 mg, tablets, orally, once daily and Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.
Study: NCT01592019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference, Patch location thigh, batch 1
Description: Reference, Patch location thigh, batch 1

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test, Patch location thigh, batch 2
Description: Test, Patch location thigh, batch 2. Three probes will be inserted at each visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference, Patch location abdomen, batch 1
Description: Reference, Patch location abdomen, batch 1

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test, Patch location abdomen, batch 2
Description: Test, Patch location abdomen, batch 2. Three probes will be inserted at each visit.
Study: NCT01352637

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DCS (D-Cycloserine ) + Prolonged Imaginal Exposure
Description: 50mg DCS (taken once a week on the day of the therapy session) + Prolonged Imaginal Exposure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DCS (D-Cycloserine ) + Virtual Reality Exposure
Description: 50mg DCS (taken once a week on the day of the therapy session) + Virtual Reality Exposure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Prolonged Imaginal Exposure
Description: Placebo (taken once a week on the day of the therapy session) + Prolonged Imaginal Exposure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (sugar pill) + Virtual Reality Exposure
Description: Placebo (taken once a week on the day of the therapy session) + Virtual Reality Exposure
Study: NCT03329963

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Lifestyle Intervention
Description: Participants in the this group will receive group educational sessions that focus on diet, exercise, and social support once a month throughout the study. The sessions will provide an opportunity for participants to discuss issues related to living with obesity and aging.Participants will also attend regular scheduled clinic visits for assessment of outcomes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: The lifestyle modification will be achieved by group behavior therapy sessions designed to have older adults acquire positive weight-control skills/attitudes, and practice weight-maintenance skills.Participants will attend weekly group sessions (10-15 persons), which will last \~75-90 minutes. Visit frequency will be decreased to every 2 wks. from 6 to 12 mos. to prevent treatment fatigue. A balanced diet will be prescribed to provide a deficit of 500-750 kcal/day from daily energy requirement.~The exercise sessions are of \~90 min duration (\~15 min warm-up of flexibility exercise, followed by \~30 min of aerobic exercise, and after a brief rest period, \~30 min of resistance training, and finally \~15 min balance exercise) conducted three times weekly supervised at our exercise facility for one year. Aerobic exercises consist of treadmill, stationary cycling, and stair climbing.
Study: NCT05105113

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Zirconia dental implant installation surgery
Description: Dental implant installation surgery using zirconia one-piece implant (Tav-dental)
Study: NCT00913393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FG-3019
Description: 3 mg/kg FG-3019 IV every 2 weeks for 22 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FG-3019
Description: 10 mg/kg FG-3019 IV every 2 weeks for 22 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV every 2 weeks for 22 weeks
Study: NCT01920152

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP
Description: Each PRP preparation requires a total of 36 ml of peripheral blood. This will be obtained via venapuncture and collected in four 9 ml extraction tubes containing 3.8% sodium citrate. The tubes are then centrifuged at 640 rpm for 8 minutes at room temperature. The 1ml plasma fraction located above the buffy coat is aspirated from each tube and dispensed into the fractioning tube. The entire PRP process takes place under laminar airflow. Immediately prior to injection, calcium chloride is is drawn up from the activator ampoule with the activation syringe and is added to the PRP fractioning tube. The activated PRP is then injected in its entirety into the hip joint under strict aseptic technique.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid
Description: Hyaluronic acid is supplied as a non-pyrogenic solution in 2.5 ml pre-filled syringes and is administered by intra-articular injection using a 22-23 gauge needle. The full 2.5 ml is injected in one joint under strict aseptic administration.
Study: NCT01350115

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LDE225
Description: supplied as 100 mg capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: supplied in capsules